RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer.
Kun WangYajie ChenZhiyuan ZhangRuiyan WuMenglong ZhouWang YangJuefeng WanLijun ShenHui ZhangYan WangXu HanJiazhou WangZhen ZhangFan XiaPublished in: Gastroenterology report (2023)
NCT04948034 (ClinicalTrials.gov).